Myeloma Patients Europe (MPE)’s Post

Congratulations to Pindara for their participation in the clinical trial DREAMM-7 and the impact they have had on the patients in this trial! The DREAMM-7 trial results have shown a benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma.   Results from the DREAMM-7 multiple myeloma clinical trial were presented at the recent ASCO plenary series displaying advancing, positive results, along with a manageable safety profile that “suggest that BVd can potentially be a new standard of care in second-line treatment or later for relapsed and refractory multiple myeloma”.   Maria-Victoria Mateos Manteca, of the Hospital Universitario de Salamanca said: “BVd demonstrated a statistically significant and clinically meaningful progression-free survival benefit, with a median progression-free survival that was 23 months longer than with DVd”.   📑 To read more about this study copy this link: DREAMM-7 Confirms Benefit of Triplet Regimen in Relapsed or Refractory Multiple Myeloma - The ASCO Post #clinicaltrial #peoplecaringforpeople #myeloma #multiplemyeloma #clinicalcare #treatment #advancingcare #medicine #healthcare

✨ **Phase IV** Clinical Trials: The Final Frontier of Patient Safety & Efficacy ✨ This week I’ve been reflecting on the essential role of *Phase IV Clinical Trials* in advancing patient care! 🚀 While earlier phases focus on proving efficacy, **Phase IV trials are vital for tracking long-term safety and effectiveness, especially in chronic diseases** where patients are treated for extended periods. With *heterogeneous patient populations*, Phase IV trials provide crucial data on how treatments work across diverse groups, identifying rare side effects and ensuring therapies are optimized for all. 🌍 I’m passionate about how *Phase IV* trials help optimize treatments for complex, chronic conditions while ensuring patient safety remains at the forefront. 💡 📊 Want to learn more? Follow my page for weekly updates! #ClinicalOperations #LeadershipDevelopment #ProjectManagement #ClinicalResearch #ClinicalTrials #DrugDevelopment #CRO #ClinicalResearchCareers

Our colleague Martina Kalle-Brune traveled to #Washington, D.C. last week to join the international Critical Care Clinical Trialists Workshop 3CT. It was an exciting meeting for all those dedicated to improving treatment and patient outcomes in critical care! Inspiring presentations and a collaborative spirit dominated the discussions on sepsis among intensive care physicians, principal investigators, patient representatives, industry, and regulatory authorities. Two sessions tackled pressing questions in sepsis research and treatment: 🧬 Endotype-guided Therapy: This discussion looked at biomarkers to provide the best possible treatments to individual patients based on their characteristics. AdrenoMed presented its perspective and experience with enibarcimab as a precision therapy for the treatment of sepsis and septic shock. 🌍 Trialists and Regulators: Can We Agree on an Endpoint?: This was a crucial discussion on clinical trial endpoints in sepsis to ensure that new therapies can be evaluated and approved efficiently, ultimately benefiting patients faster. Survival, organ function and quality of life was found to be key! Many thanks to the workshop organizers and participants for the fruitful meeting! Learn more: https://lnkd.in/dcjwN_XC Alexandre Mebazaa Pierre-Francois Laterre Peter Pickkers Nathan Nielsen Michelle Chew Jacqueline Duda   #Adrenomed #3CTWorkshop #CriticalCare #ClinicalTrials #MedicalInnovation

In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. https://ja.ma/3yCtPRu

Did you know that chronic diseases account for a whopping 84% of deaths globally? That's a staggering number. Digital therapeutics (DTx) are transforming the way we treat chronic conditions. These aren't just apps; they're evidence-based treatments delivered right to your smartphone for personalized care, improved engagement, and better outcomes for chronic conditions like diabetes, hypertension, and mental health. Read the article to learn more! Innovation & Tech Today American Medical Association American Hospital Association Digital Health Insights Becker's Healthcare BioSpace McKinsey & Company FDA Manisha Khadge Pravin Uttarwar #digitaltherapeutics #personalizedmedicine #healthcare #wellness #healthtech #futureofhealthcare

The latest supplement to JCAD reviews response data from the over 2,000 biologic-experienced patients included in the UCB bimekizumab #psoriasis clinical trials and discusses how this data can inform real-world practice and patient counseling. Click here to read: https://ow.ly/agZL50RAygy Many thanks to Omar Noor, MD, FAAD, and Jacob Beer, MD for providing their review and commentary.

Join us for our upcoming webinar, Management of Dermatomyositis: Focus on IG Therapy. In this live educational webinar sponsored by Octapharma, Dr. Christina Charles-Schoeman will discuss intravenous immunoglobulin (IVIg) therapy for adults with dermatomyositis (DM). Learn how IVIg therapy works, how it affects patient outcomes, and why it's important for patients to understand IVIg within the current treatment paradigm. The webinar will be followed by a Q&A session. Find all the details and register today! https://lnkd.in/e3fSF3Ff #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda

[STA®-Liatest® D-Di Plus to enhance VTE diagnostis and patient care] 💡 23% of samples with a positive Siemens result were negative when tested with Stago. This data highlights the potential of Stago D-Dimer Tests to reduce unnecessary investigations and improve clinical decisions for patients with suspected VTE (Venous ThromboEmbolism). A recent study from The New Zealand Medical Journal compared 2️⃣ D-dimer assays: INNOVANCE® DDimer (Siemens) and STA®-Liatest® D-Di Plus (Stago) 👉 https://lnkd.in/egrxWnNw 🔎 Stago assay also showed better resistance to antibody interference, ensuring more reliable and accurate results. By using STA®-Liatest® D-Di Plus, healthcare providers can enhance VTE diagnostis and patient care. 👉 https://lnkd.in/ep7ca73K #Diagnostics #Healthcare #VTE #DDimer #PatientCare DAVID COURTOIS Alex S. Aliénor Auby Tara Simpson, MBA Nichole Howard, MBA Paul Riley Clémence Chesne Hadison Yip Yannig QUEREL

Have you heard of our Trooper Study? Did you know Digital Pulmonary Rehabilitation is safe and patients outcomes where inline with what the class delivered? The research team at my mhealth have been working hard to ensure the support it provides is evidence backed, and guaranteed to see results. The team has undertaken a number of clinical trials and real-world studies to ensure the platform is effective and able to support health services and patients. The Trooper Study; ➡ An RCT comparing online versus conventional pulmonary rehabilitation for patients with COPD. ➡ Results showed a 6-week programme of online supported PR was non-inferior to a conventional model delivered in face-to-face sessions in terms of impact on the 6-minute walk test distance and symptom scores, and was safe and well tolerated by patients. To learn more about the evidence behind our digital therapeutics, check out our peer-reviewed studies and real-world evidence here https://lnkd.in/eBfdgF6Z #PulmonaryRehabWeek24 #LungHealth #COPD #DigitalHealth

🔥🔥HOT TOPIC 🔥🔥 Join us for a live discussion on PATIENTS AND DOCTORS clinical trial awareness! Together with Ewa Stawiarska, M.D. (@doktora_od_7_bolesci), we’ll explore the critical role of clinical trials in advancing treatments and why awareness among both patients and physicians needs improvement. We’ll cover: ✅Patients value trials but lack understanding: While 84.5% see trials as vital, 59% don’t know where they’re conducted. ✅Doctors are key: 63.5% of patients prefer learning about trials from their doctor, but 44.9% say trials are rarely discussed during visits. ✅Positive patient experiences: 93.4% of trial participants would join another study, and 52.6% rate trial care better than standard care. ✅Barriers and solutions: How can we reduce disruptions for participants and engage more patients and physicians in trial discussions? 🕒 26.11.2024 20:00 on my Instagram (@cra_mamasita) Let’s work together to build awareness and unlock the potential of clinical trials! Above data from the report: https://lnkd.in/dtqHgvHd Additional report: https://lnkd.in/d-gF9xY3 #ClinicalTrials #HealthEducation #PatientAwareness #LiveDiscussion #FutureOfMedicine